# Alembic Pharmaceuticals Ltd (APLLTD)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹762.3
Day Change: +0.87%
52W High: ₹1107.9
52W Low: ₹635.8
Market Cap: ₹14,165 Cr

## Valuation
P/E: 22.47
P/B: 2.5
EPS: ₹32.07
Book Value: ₹288.64
Dividend Yield: 0%

## Returns
1Y Return: -16.29%

## Profitability
ROE: 12.36%
ROCE: 13.11%
Debt/Equity: 0.25
Revenue Growth: 5.9%
Profit Growth: 29.2%
EBITDA Margin: 15.85%
Operating Margin: 8.8%

## About
Alembic Pharmaceuticals Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Alembic Pharmaceuticals Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement: Alembic Pharmaceuticals Limited Passes ANVISA (Brazil) GMP Inspection For Its API-III Facility At Karakhadi.
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-25T12:00:11.977Z
Price History Updated: 2026-05-25T05:24:20.519Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:24:20.519Z
Quant Updated: 2026-05-25T05:24:20.519Z
Sentiment Updated: 2026-05-25T05:24:20.519Z
Financials Status: current
Financials Updated: 2026-05-18T09:31:53.353Z
Financials Last Attempt: 2026-05-18T09:31:53.353Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹2056 Cr
Operating Profit: ₹403 Cr (OPM 20%)
Net Profit: ₹283 Cr
Tax: ₹359 Cr

## Annual P&L History
Mar 2016: Rev ₹2056Cr | PAT ₹283Cr | OPM 20%
Mar 2017: Rev ₹3166Cr | PAT ₹720Cr | OPM 32%
Mar 2018: Rev ₹3105Cr | PAT ₹403Cr | OPM 20%

## Balance Sheet (Mar 2016)
Total Assets: ₹1641 Cr
Total Liabilities: ₹1641 Cr
Borrowings: ₹264 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Chirayu Ramanbhai Amin, Executive Chairman
- Shaunak Chirayu Amin, MD & Executive Director
- Pranav Chirayu Amin, MD & Executive Director
- G.  Krishnan, Chief Financial Officer
- Sachin  Ghosalkar, Senior Vice President of SCM & Operations

---
Source: rupiya.io/stocks/aplltd
Disclaimer: For research and education only. Not investment advice.